Actively Recruiting
Effect of Melatonin in Patients With Diabetic Peripheral Neuropathy
Led by Ain Shams University · Updated on 2025-08-06
60
Participants Needed
1
Research Sites
52 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The aim of the current study is to measure the effect of melatonin as adjunct therapy on oxidative stress, inflammatory markers and clinical outcome in type 2 diabetic patients with diabetic peripheral neuropathy.
CONDITIONS
Official Title
Effect of Melatonin in Patients With Diabetic Peripheral Neuropathy
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age between 40 and 75 years
- Diagnosed with type 2 diabetes mellitus for at least 1 year
- Diagnosed with diabetic peripheral neuropathy
- On stable antidiabetic medication for at least 1 month before and during the study
You will not qualify if you...
- Having autoimmune disorders such as lupus or rheumatoid arthritis
- Having thyroid diseases
- Having peripheral arterial disease
- Having cancer
- Severe kidney or liver dysfunction
- Diagnosed with neurodegenerative diseases
- Active infection
- Using medications or supplements that cause or treat peripheral neuropathy
- Alcohol consumption or substance abuse
- Using antioxidant supplements or anti-inflammatory medicines during or within 3 months before enrollment
- Pregnancy, lactation, or planning to become pregnant during the study
- Allergy to melatonin
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Ain Shams University hospital
Cairo, Egypt
Actively Recruiting
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here